Our results suggest a potential new combination therapy of olaparib and TRAIL for pancreatic cancer independent of BRCA2 mutations and may extend the limited applicability of PARP inhibitors in this disease. The gene discussed is PARP1; the disease is familial pancreatic carcinoma.